Literature DB >> 10781378

Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation.

S A Miller1, C H Selzman, B D Shames, H A Barton, S M Johnson, A H Harken.   

Abstract

BACKGROUND: Observational data strongly suggest an association between Chlamydia pneumoniae and atherosclerotic cardiovascular disease. However, few studies have mechanistically linked C. pneumoniae to vascular remodeling. The purpose of the present study was to examine the mechanistic relationship between C. pneumoniae and human vascular smooth muscle cell (VSMC) physiology. We sought to determine the influence of human VSMC infection by C. pneumoniae on (1) VSMC proliferation and (2) activation of the proinflammatory and proliferative transcription factors nuclear factor kappaB (NF-kappaB) and activator protein 1 (AP-1).
MATERIALS AND METHODS: C. pneumoniae was grown and isolated from Hep 2 cells. Human aortic VSMCs were inoculated with C. pneumoniae in the presence and absence of the azalide antibiotic azithromycin. Cell proliferation was assayed by direct cell counting 48 h following infection. Two hours following infection, nuclear extracts were isolated, and activation of both NF-kappaB and AP-1 was assessed by electrophoretic mobility shift assay.
RESULTS: Compared with control, C. pneumoniae infection stimulated VSMC proliferation (P < 0.05) and induced both NF-kappaB and AP-1 DNA binding activity. These effects were eliminated by concurrent treatment with azithromycin.
CONCLUSIONS: VSMC infection with C. pneumoniae activates proliferative intracellular signals and stimulates cell growth. These data implicate C. pneumoniae as a pathogenic mediator and a potential therapeutic target in the prevention of atherosclerotic disease. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781378     DOI: 10.1006/jsre.2000.5847

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

1.  Chlamydia pneumoniae activates epithelial cell proliferation via NF-kappaB and the glucocorticoid receptor.

Authors:  Mikael M Cornelsen Gencay; Michael Tamm; Allan Glanville; André P Perruchoud; Michael Roth
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

2.  Transcription factor complex AP-1 mediates inflammation initiated by Chlamydia pneumoniae infection.

Authors:  Anyou Wang; Mufadhal Al-Kuhlani; S Claiborne Johnston; David M Ojcius; Joyce Chou; Deborah Dean
Journal:  Cell Microbiol       Date:  2012-12-16       Impact factor: 3.715

Review 3.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

4.  The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells.

Authors:  S Iwamoto; T Kumamoto; E Azuma; M Hirayama; M Ito; K Amano; M Ido; Y Komada
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

5.  AP-1 Transcription Factor Serves as a Molecular Switch between Chlamydia pneumoniae Replication and Persistence.

Authors:  S Krämer; P Crauwels; R Bohn; C Radzimski; M Szaszák; M Klinger; J Rupp; G van Zandbergen
Journal:  Infect Immun       Date:  2015-04-20       Impact factor: 3.441

6.  Chlamydia trachomatis infection induces cleavage of the mitotic cyclin B1.

Authors:  Zarine R Balsara; Shahram Misaghi; James N Lafave; Michael N Starnbach
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

7.  Chlamydia pneumoniae and Cardiovascular Disease.

Authors:  Maria Kolia; Ignatius William Fong
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

Review 8.  Azithromycin in viral infections.

Authors:  Madeleine E Oliver; Timothy S C Hinks
Journal:  Rev Med Virol       Date:  2020-09-23       Impact factor: 11.043

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.